Glomerulonephritis (GN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Glomerulonephritis (GN) is a subgroup of renal diseases caused by immune-mediated damage to the basement membrane, mesangium, or capillary endothelium. This leads to symptoms such as hematuria, proteinuria, and azotemia. GN can be classified as acute or progressive, potentially leading to chronic kidney and end-stage renal disease. There are several ways to classify GN based on clinical presentation, including the nephrotic or nephritic syndrome, or based on the underlying immune processes, with five forms: immune-complex, pauci-immune, anti-glomerular basement membrane, monoclonal Ig, and C3 glomerulopathy. Regardless of the classification, the pathogenesis of GN is immune-mediated and involves both humoral and cell-mediated pathways. The following inflammatory response can cause fibrosis and depends on the target of immune-mediated damage, which can vary based on the type of GN. The underlying mechanisms activate the complement system and coagulation cascade, releasing pro-inflammatory cytokines and growth factors, ultimately leading to glomerulosclerosis and renal dysfunction.
·
In the USA, the annual incidence of
glomerulonephritis is estimated to be 57 cases per 100,000 individuals.
Thelansis’s “Glomerulonephritis (GN)
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2022 To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Glomerulonephritis (GN) treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
KOLs insights
of Glomerulonephritis (GN) across the 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Glomerulonephritis (GN) Market Forecast Patient-Based
Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with
sourcing, Market Event, and Product Event, Country specific Forecast Model,
Market uptake and patient share uptake, Attribute Analysis, Analog Analysis,
Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment